Takotsubo syndrome caused by subconjunctival injection of a mydricaine analogue

Rasiah, Sulakshan; Finger, Robert P.; MacIsaac, Andrew

doi:10.1111/ceo.12729

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other cases described cardiological effects, such as Tako‐Tsubo 8 or atrial fibrillation, 9 following the use of mydricaine, which contains atropine and is used during vitreoretinal surgery to maintain mydriasis.…”

Section: Discussionmentioning

confidence: 99%

Central anticholinergic syndrome secondary to atropine eye drops: A case study

Soletchnik

Rousseau

Gonzalez

et al. 2022

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Central anticholinergic syndrome secondary to atropine eye drops: A case study

Soletchnik

Rousseau

Gonzalez

et al. 2022

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…However, causality between the use of beta-blockers and/or aspirin among TTS with KF patients and the outcome has not been proven in prospective trials until today. There is a bevy of case reports that describe the development of an acute phase of TTS after the application of α- or β-agonists [ 29 , 34 , 35 ]. If a ß-agonist may provoke an acute phase of TTS, it seems to be consequent that a ß-blocker may impact the presence of the TTS pattern or/or outcome.…”

Section: Discussionmentioning

confidence: 99%

Kidney Failure among Patients with Takotsubo Syndrome or Myocardial Infarction: A Retrospective Analysis

Bill¹,

El‐Battrawy

Kummer

et al. 2022

JCDD

View full text Add to dashboard Cite

Background: Takotsubo syndrome (TTS) is a syndrome with ambiguous pathophysiology. Impaired kidney function (KF) seems to impact the outcome of patients with TTS. We hypothesized that KF worsens the outcome among TTS patients and furthermore, TTS patients with concomitant KF experience more adverse events compared to myocardial infarction (MI) patients with concomitant KF. Methods and Results: This retrospective single-center study comprised two groups (cohorts) of patients including patients with TTS and concomitant KF (n = 61, 27.1%) and patients with MI and concomitant KF (n = 164, 72.9%). The clinical outcomes were delineated as short-term outcomes defined as in-hospital adverse events during index hospitalization and long-term outcomes defined as adverse events over five-year clinical follow-ups. All-cause mortality, stroke, cardiopulmonary resuscitation (CPR), life-threatening arrhythmias, need for respiratory support, and cardiogenic shock with subsequent use of inotropic agents during index hospitalization were denoted as in-hospital adverse events. All-cause mortality, rehospitalization due to heart failure, stroke, thromboembolic events, and the recurrence of primary pathology (TTS and MI) were analyzed during five-year follow-ups after index hospitalization. A higher mortality rate was noted among TTS patients with KF compared to TTS without KF. In addition, in-hospital event rates in patients with TTS and concomitant KF compared to MI and concomitant KF were comparable with the exception of a higher rate of respiratory support in TTS patients. The mortality rate was significantly higher among patients with TTS and KF at 4 years (29.5% vs. 15.9%, p = 0.02) and 5 years (34.4% vs. 20.7%, p = 0.03) in comparison to patients with MI and concomitant KF. In contrast, the rate of re-hospitalization related to heart failure was higher at 30 days, and at one-, four-, and five-year follow-ups in patients suffering from MI and KF compared to TTS and concomitant KF. Additionally, the recurrence of MI after 4 and 5 years was higher than the recurrence of TTS (4.9% vs. 15.2%; 4.9% vs. 16.5%). There were no differences in life-threatening arrhythmias and stroke in both groups. Conclusions: Patients with TTS and concomitant KF have higher all-cause mortality when compared to MI and concomitant KF. The mechanisms responsible remain to be determined.

show abstract

Atropine/epinephrine/lidocaine

2017

Reactions Weekly

View full text Add to dashboard Cite

Takotsubo syndrome caused by subconjunctival injection of a mydricaine analogue

Cited by 4 publications

References 5 publications

Central anticholinergic syndrome secondary to atropine eye drops: A case study

Central anticholinergic syndrome secondary to atropine eye drops: A case study

Kidney Failure among Patients with Takotsubo Syndrome or Myocardial Infarction: A Retrospective Analysis

Atropine/epinephrine/lidocaine

Contact Info

Product

Resources

About